Leona A. Holmberg

Oncology

825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 102 publications

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Journal: Bone marrow transplantation

Published: April 01, 2026

Cytomegalovirus After Autologous Hematopoietic Cell Transplantation: Impact on Outcome and A Personalized Risk-Adapted Prevention Strategy.

Cytomegalovirus After Autologous Hematopoietic Cell Transplantation: Impact on Outcome and A Personalized Risk-Adapted Prevention Strategy.

Journal: Transplantation and cellular therapy

Published: March 31, 2026

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Journal: Blood advances

Published: March 02, 2026

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Journal: Blood advances

Published: March 02, 2026

Plant-based whole-food diets are feasible during autologous stem cell transplantation and are associated with dose-dependent microbiome modulation: Results from a pilot clinical trial.

Plant-based whole-food diets are feasible during autologous stem cell transplantation and are associated with dose-dependent microbiome modulation: Results from a pilot clinical trial.

Journal: medRxiv : the preprint server for health sciences

Published: February 12, 2026

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

Autologous and allogeneic hematopoietic cell transplantation in children and adults with high-risk anaplastic large cell lymphoma.

Autologous and allogeneic hematopoietic cell transplantation in children and adults with high-risk anaplastic large cell lymphoma.

Journal: Frontiers in oncology

Published: January 11, 2026

Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma.

Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma.

Journal: Blood neoplasia

Published: December 19, 2025

Impact of Post-Autologous Peripheral Blood Stem Cell Transplant (ASCT)- Granulocyte Colony Stimulating Factor (G-CSF) on Toxicity Profiles in Hodgkin Lymphoma (HL) Patients Receiving Pre-ASCT Immune Checkpoint Inhibitors (ICI).

Impact of Post-Autologous Peripheral Blood Stem Cell Transplant (ASCT)- Granulocyte Colony Stimulating Factor (G-CSF) on Toxicity Profiles in Hodgkin Lymphoma (HL) Patients Receiving Pre-ASCT Immune Checkpoint Inhibitors (ICI).

Journal: Transplantation and cellular therapy

Published: October 05, 2025

NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.

NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: May 09, 2025

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial.

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: August 05, 2024

Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.

Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 24, 2024

Showing 1-12 of 102

Last Updated: 09/26/2026